false000092111400009211142024-08-132024-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 13, 2024

ARMATA PHARMACEUTICALS, INC.

(Exact name of Registrant as specified in its charter)

Washington

001-37544

91-1549568

(State or other jurisdiction of
incorporation or organization)

(Commission File Number)

(IRS Employer Identification No.)

5005 McConnell Avenue

Los Angeles, California

90066

(Address of principal executive offices)

(Zip Code)

(310) 655-2928

(Registrant’s Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol(s)

    

Name of Each Exchange on Which Registered

Common Stock

ARMP

NYSE American

Item 2.02Results of Operations and Financial Condition.

On August 13, 2024, Armata Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2024, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

Exhibit
No.

    

Description

99.1

Press Release, dated August 13, 2024.

104

Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2024

Armata Pharmaceuticals, Inc.

By:

/s/ Richard Rychlik

Name:

Richard Rychlik

Title:

Vice President, Corporate Controller

Graphic

Exhibit 99.1

Armata Pharmaceuticals Announces Second Quarter 2024 Results and

Provides Corporate Update

LOS ANGELES, CA, August 13, 2024 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2024, and provided a corporate update.  

Second Quarter 2024 and Recent Developments:

Announced completion of enrollment in its Tailwind Phase 2 clinical study of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) and chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infection. The last patient final follow-up visit occurred on August 7. Armata anticipates topline data from the Tailwind study in the second half of 2024.
Received $5.25 million of additional non-dilutive funding from the U.S. Department of Defense pursuant to a previously-announced grant. The award is partially supporting advancement of the Phase 2a portion of the diSArm study of intravenous AP-SA02 as a potential treatment for Staphylococcus aureus (S. aureus) bacteremia.
Further advanced bacteriophage science through presentations and publications:
oDelivered a presentation on advancing bacteriophage therapy at Viruses of Microbes 2024, which was held July 15-19, 2024, in Cairns, Australia.
Completed the build-out of its advanced biologics manufacturing facility with five current good manufacturing practice (“cGMP”) clean rooms, including a state-of-the-art automated fill and finish suite.

“During the second quarter and subsequent period, we made meaningful progress across both of our clinical programs, keeping us on track to potentially initiate pivotal studies next year,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “Regarding AP-PA02, which we are developing as an inhaled treatment for chronic P. aeruginosa lung infections, I am pleased to report that we recently completed enrollment and the last patient visit in our Phase 2 Tailwind study in subjects with NCFB, and we plan to announce topline data later this year.”    

“For AP-SA02, we continued to advance our Phase 2a diSArm study of intravenous AP-SA02 as a potential treatment for S. aureus bacteremia. We are grateful to the Department of Defense for its ongoing financial support, which provides us with critical non-dilutive funding. We look forward to completing the diSArm study later this year and identifying the optimal dose of AP-SA02 to be tested in a larger definitive study.”

“Also, during the second quarter, we completed the build-out of our state-of-the-art cGMP manufacturing facility, giving us the ability to support our late-stage clinical trials, potential partnerships, and potential commercial production.”

“Our mission has long been the execution of rigorously designed, randomized clinical studies that demonstrate the safety and efficacy of our multi-phage candidates to support eventual registration, and I am very pleased with our sustained progress during the second quarter and through the first half of the year,” Dr. Birx concluded.

Second Quarter 2024 Financial Results

Grant Revenue. The Company recognized no grant revenue for the three months ended June 30, 2024. The Company recognized approximately $1.0 million of grant revenue in the comparable period in 2023 which represents Medical Technology Enterprise Consortium’s share of the costs incurred for the Company’s AP-SA02 program for the treatment of Staphylococcus aureus bacteremia.

Research and Development. Research and development expenses for the three months ended June 30, 2024 were approximately $8.5 million as compared to approximately $8.3 million for the comparable period in 2023. The Company continues to invest in clinical related expenses associated with its primary development programs.

General and Administrative. General and administrative expenses for the three months ended June 30, 2024 were approximately $3.4 million as compared to approximately $2.4 million for the comparable period in 2023. The increase was mainly related to an increase of $1.0 million in stock-based compensation as a result of increased awards granted during the first quarter of 2024.

Loss from Operations. Loss from operations for the three months ended June 30, 2024 was $11.9 million as compared to a loss from operations of approximately $9.6 million for the comparable period in 2023.

Cash and Equivalents. As of June 30, 2024, Armata held approximately $26.4 million of unrestricted cash and cash equivalents, as compared to $13.5 million as of December 31, 2023.

As of August 13, 2024, there were approximately 36.2 million common shares outstanding.  


Graphic

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Forward Looking Statements

This communication contains “forward-looking” statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata’s future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata’s actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions. These forward-looking statements reflect management’s beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata’s development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata’s estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption “Risk Factors” and elsewhere in Armata’s filings and reports with the SEC, including in Armata’s Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Media Contacts:

At Armata:

Pierre Kyme

ir@armatapharma.com

310-665-2928

Investor Relations:

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569


Graphic

Armata Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

    

June 30, 2024

    

December 31, 2023

    

Assets

Current assets

Cash and cash equivalents

$

26,405

$

13,523

Prepaid expenses and other current assets

 

3,256

 

2,265

Other receivables

1,242

3,363

Total current assets

 

30,903

 

19,151

Property and equipment, net

 

13,474

 

12,559

Operating lease right-of-use asset

 

43,671

 

44,717

Intangible assets, net

13,746

13,746

Other long term assets

 

6,519

 

8,190

Total assets

$

108,313

$

98,363

Liabilities and stockholders’ deficit

 

  

 

  

Total current liabilities

$

123,181

$

16,461

Long-term debt

82,307

Operating lease liabilities, net of current portion

28,156

28,583

Deferred tax liability

3,077

3,077

Total liabilities

 

154,414

 

130,428

Stockholders’ deficit

 

(46,101)

 

(32,065)

Total liabilities and stockholders’ deficit

$

108,313

$

98,363


Graphic

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

Three Months Ended

Six Months Ended

June 30, 

June 30, 

    

2024

    

2023

    

2024

    

2023

    

Grant revenue

$

$

980

$

966

$

1,776

Operating expenses:

Research and development

 

8,475

8,259

16,491

17,863

General and administrative

 

3,439

2,350

6,617

4,888

Total operating expenses

11,914

10,609

23,108

22,751

Operating loss

 

(11,914)

(9,629)

(22,142)

(20,975)

Interest income

 

221

46

273

64

Interest expense

 

(2,718)

(4,538)

Change in fair value of convertible debt

23,397

6,036

10,372

2,874

Net income (loss)

$

8,986

$

(3,547)

$

(16,035)

$

(18,037)

Per share information:

Net income (loss) per share, basic

$

0.25

$

(0.10)

$

(0.44)

$

(0.50)

Weighted average shares outstanding, basic

36,154,521

36,068,130

36,139,873

36,056,649

Net loss per share, diluted

$

(0.25)

$

(0.17)

$

(0.45)

$

(0.50)

Weighted average shares outstanding, diluted

58,246,626

56,544,698

58,231,978

36,056,649


Graphic

Armata Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

Six Months Ended June 30, 

 

    

2024

    

2023

 

Operating activities:

Net loss

$

(16,035)

$

(18,037)

Adjustments required to reconcile net loss to net cash used in operating activities:

Depreciation and amortization expense

632

458

Stock-based compensation expense

1,869

1,118

Change in fair value of convertible debt

(10,372)

(2,874)

Non-cash interest expense

4,538

Change in right-of-use asset

960

Changes in operating assets and liabilities:

(2,353)

(10,295)

Net cash used in operating activities

 

(20,761)

 

(29,630)

Investing activities:

 

  

 

  

Purchases of property and equipment

(1,616)

(2,232)

Net cash used in investing activities

 

(1,616)

 

(2,232)

Financing activities:

 

  

 

  

Proceeds from issuance of convertible debt, net of issuance costs

29,226

Proceeds from issuance of long-term debt, net of issuance costs

34,889

Proceeds from exercise of stock options

130

Net cash provided by financing activities

 

35,019

 

29,226

Net increase (decrease) in cash, cash equivalents and restricted cash

 

12,642

 

(2,636)

Cash, cash equivalents and restricted cash, beginning of period

 

19,243

 

20,812

Cash, cash equivalents and restricted cash, end of period

$

31,885

$

18,176

Six Months Ended June 30, 

2024

    

2023

Cash and cash equivalents

$

26,405

$

12,456

Restricted cash

5,480

5,720

Cash and restricted cash

$

31,885

$

18,176


v3.24.2.u1
Document and Entity Information
Aug. 13, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 13, 2024
Entity Registrant Name ARMATA PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code WA
Entity File Number 001-37544
Entity Tax Identification Number 91-1549568
Entity Address, Address Line One 5005 McConnell Avenue
Entity Address, City or Town Los Angeles
Entity Address State Or Province CA
Entity Address, Postal Zip Code 90066
City Area Code 310
Local Phone Number 655-2928
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ARMP
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Central Index Key 0000921114
Amendment Flag false
v3.24.2.u1
Document Information
Aug. 13, 2024
Document Information:  
Document Type 8-K
Amendment false
CIK 0000921114
Registrant Name ARMATA PHARMACEUTICALS, INC.
Period End Date Aug. 13, 2024

Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Armata Pharmaceuticals Charts.
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Armata Pharmaceuticals Charts.